IN THE CLAIMS

21. (Currently Amended) Monocyclic compounds of formula (I)

wherein:



(I)

X_1, X_2, X_3, X_4 are the same or different, and are selected from the group consisting of -CONR-, -NRCO-, $-CH_2-NR-$, and $-NR-CH_2-$ where R is selected from the group consisting of H, C_{1-3} alkyl, and benzyl;

f and m are the same or different, and are a number selected from the group consisting of 0, 1 and 2;

R_1 and R_2, are the same or different, and represent:

$-(CH_2)_r Ar$ where r is 0, 1 or 2 and Ar is an aromatic group selected from the group consisting of benzene, naphthalene, thiophene, benzothiophene, pyridine, quinoline, indole, furan, benzofuran, thiazole, benzothiazole, imidazole, benzoimidazole, optionally substituted with up to 2 substituents selected from the group consisting of C_{1-3} alkyl, C_{1-3} haloalkyl, C_{1-3} alkyloxy, C_{2-4} amino-alkyloxy, halogens, OH, NH_2, CN, and NR_6R_7, where R_6 and R_7, same or different, are H or C_{1-3} alkyl,

R_3 is $-(CH_2)_rAr_1$ where r is 0, 1 or 2 and Ar_1 is an aromatic group selected from the group consisting of benzene, naphthalene, thiophene, benzothiophene, pyridine, quinoline, indole, furan, benzofuran, thiazole, benzothiazole, imidazole, and benzimidazole,

optionally substituted with up to 2 groups selected from the group consisting of C_{1-3} alkyl, C_{1-3} haloalkyl, C_{1-3} alkyloxy, C_{2-4} amino-alkyloxy, halogens, OH, NH_2, and NR_6R_7, where R_6 and R_7, same or different, are H or C_{1-3} alkyl,

R_5 is H,

R_4 is $-NR_8R_9$;$-N(R_{11})CO(CH_2)_h R_{12}$; or $-COR_{13}$; where R_8 is H or C_{1-3} alkyl; h is 0, 1, 2 or 3; and R_9 is selected from the group consisting of methanesulfonyl, tosyl, tetrahydropyranyl, tetrahydrothiopyranyl optionally mono or di-substituted by oxygen on the S atom, piperidyl, optionally substituted on the N-atom by a C_{1-3} alkyl, C_{1-3} acyl, aminosulfonyl, or methanesulfonyl; or a group $-(CH_2)_gR_{10}$ where g is 1,2, or 3 and R_{10} is selected from the group consisting of morpholine, furan and CN;

or R_8 and R_9 together with the N atom to which they are linked form a piperazine optionally substituted at the other N atom by a C_{1-3} alkyl, C_{1-3} acyl or methanesulfonyl;

R_{11} is H or C_{1-3} alkyl; h is 0, 1, 2 or 3; and R_{12} is selected from the group consisting of morpholine, pyrrolidine optionally substituted with a hydroxy or hydroxymethyl, piperidine optionally substituted with a 4-hydroxy or 4-carboxyamido, piperazine optionally substituted on the other N-atom by C_{1-3} alkyl, triazole, tetrazole, 5-mercapto-tetrazole, furan, thiophene, and thiomorpholine, optionally mono or di-oxygenated on the S-atom;

R_{13} is a member selected from the group consisting of morpholine and piperazine optionally substituted by a C_{2-6} alkyl containing one or more hydroxy groups;

their enantiomers and mixtures thereof, their diastereoisomers, and their pharmaceutically acceptable salts.

22. (Previously Presented) Compound according to Claim 21 wherein:

f is 1

m is 0

X_1, X_2, X_3, X_4, are the same or different and are a member selected from the group consisting of -CONR- and -NRCO-,

where R is H or methyl,

R_1 and R_2 are the same or different, are:

$-CH_2Ar$ wherein Ar is an aromatic group selected from the group consisting of benzene, pyridine, indole, optionally substituted with up to two substituents selected from the group consisting of C_{1-3} alkyl, C_{1-3} haloalkyl, C_{1-3} alkyloxy, C_{2-4} amino alkyloxy, halogens, OH, NH_2, CN, and NR_6R_7, where R_6 and R_7, same or different, and are H or C_{1-3} alkyl;

R_3 is $-CH_2Ar_1$ wherein Ar_1 is an aromatic group selected from the group consisting of alpha naphthyl, beta naphthyl, phenyl, and phenyl substituted with up to two substituents selected from the group consisting of C_{1-3} alkyl, C_{1-3} haloalkyl, C_{1-3}alkyloxy, halogens, OH, and NH_2.

23. (Previously Presented) Compounds according to Claim 22 wherein:

- X_1, X_2, X_3, X_4 are -CONH-,
- R_1 is indol-3-yl-methyl
- R_2 is phenyl-methyl optionally substituted with up to two substituents selected from the group consisting of chlorine, fluorine, CF_3, OH and CN; or is selected from the group consisting of 3-pyridyl-methyl and 4-pyridyl-methyl;
- R_3 is benzyl.

24. (Previously Presented) Compounds according to claim 23 wherein:

R_4 is a group NR_8R_9 wherein:

R_8 is H or methyl;

R_9 selected from the group consisting of 4-tetrahydropyranyl, 4-tetrahydrothiopyranyl, 1-oxo-tetrahydrothiopyran-4-yl, 1,1-dioxo-tetrahydrothiopyran-4-yl, N-methyl-4-piperidinyl, N-methanesulfonyl-4-piperidinyl, and N-aminosulfonyl-4-piperidinyl,

or R_8 and R_9 together with the N atom to which they are linked represent N-methyl-piperazinyl, N-acetyl-piperazinyl or N-methanesulfonyl-piperazinyl.

25. (Currently Amended) Compounds according to Claim 24 represented by:

i) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

ii) cyclo{Suc[1-(S)-(4-tetrahydropyranyl)amino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

iii) cyclo{Suc[1-(R)-(1-methyl-piperidin-4-yl)amino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

iv) cyclo{Suc[1-(R)-(4-tetrahydrothiopyranyl)amino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

v) cyclo{Suc[1-(R)-(1-oxo-tetrahydrothiopyran-4-yl)amino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

vi) cyclo{Suc[1-(R)-(1,1-dioxo-tetrahydrothiopyran-4-yl)amino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

vii)cyclo{Suc[1-(R)-N-methyl-N-(4-tetrahydropyranyl)amino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

viii) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Tyr-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

ix) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Phe(4-F)-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

x) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Phe(3,5-F)-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

xi) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Phe(4-CN)-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

xii) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Phe(4-$CF[3]_3$)-[(R)-NH-CH (CH_2-C_6H_5)-CH_2NH]}

xiii) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Ala(4-pyridyl)-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

xiv) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Ala(3-pyridyl)-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

xv) cyclo{Suc[1-(R)-(1-methylsulfonyl-piperidin-4-yl)amino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

xvi) cyclo{Suc[1-(R)-(1-aminosulfonyl-piperidin-4-yl)amino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

xvii) cyclo{Suc[1-(R)-4-methyl-piperazin-1-yl]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

xviii) cyclo{Suc[1-(R)-4-acetyl-piperazin-1-yl]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]} or

xix) cyclo{Suc[1-(R)-4-methylsulfonyl-piperazin-1-yl]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}.

26. (Previously Presented) Compounds according to Claim 23 wherein: R_4 represents a group NR_8R_9, where R_8 is H and R_9 is methanesulfonyl, tosyl or a group -$(CH_2)_gR_{10}$, wherein g is 1 or 2 and R_{10} is morpholine, furan, or CN.

27. (Previously Presented) Compounds according to claim 26 represented by:

xx) cyclo{Suc[1-(S)-methylsulfonylamino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

xxi) cyclo{Suc[1-(R)-methylsulfonylamino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

xxii) cyclo{Suc[1-(S)-(4-methylphenyl)sulfonylamino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

xxiii) cyclo{Suc[1-(R)-(4-methylphenyl)sulfonylamino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

xxiv) cyclo{Suc[1-(S)-2-(4-morpholino)ethylamino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

xxv) cyclo{Suc[1-(R)-2-(4-morpholino)ethylamino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

xxvi) cyclo{Suc[1-(R)-(2-furyl)methylamino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

or

xxvii) cyclo{Suc[1-(R)-cyanomethylamino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}.

28. (Currently Amended) Compounds according to claim 23 wherein: R_4 is a group - $N(R_{11})CO(CH_2)_h$-R_{12} wherein R_{11} is H, h is 0 or 1, and R_{12} is selected from the group consisting of 1-tetrazolyl, 5-mercapto-tetrazol-1-yl, 1-triazolyl, furanyl, thiophenyl, morpholine, 4-hydroxy-piperidine, 4-carboxyamido-piperidine, 3-hydroxy-

pyrrolidine, 2-hydroxymethylpyrrolidine, 4-methyl-piperazine, and 1-oxo-thiomorpholine[,].

29. (Currently Amended) Compounds according to Claim 28 represented by:

xxviii) cyclo{Suc[1-(R)-2-(4-morpholino)acetylamino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

xxix) cyclo{Suc[1-(S)-2-(4-morpholino)acetylamino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

xxx) cyclo{Suc[1-(S)-2-(tetrazol-1-yl)acetylamino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

xxxi) cyclo{Suc[1-(R)-2-(tetrazol-1-yl)acetylamino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

xxxii) cyclo{Suc[1-(S)-2-(5-mercapto-tetrazol-1-yl)acetylamino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

xxxiii) cyclo{Suc[1-(R)-2-([1,2,4]triazol-1-yl)acetylamino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)CH_2NH]}

xxxiv) cyclo{Suc[1-(R)-2-(furanyl)carbonylamino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

xxxv) cyclo{Suc[1-(R)-2-(thiophen-3-yl)acetylamino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

xxxvi) cyclo{Suc[1-(R)-(4-morpholino)carbonylamino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

xxxvii) cyclo{Suc[1-(R)-2-(4-hydroxy-piperidin-1-yl)acetylamino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

xxxviii) cyclo{Suc[1-(R)-2-(4-aminocarbonyl-piperidin-1-yl)acetylamino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

xxxix) cyclo{Suc[1-(R)-2-(3-hydroxy-pyrrolidin-1-yl)acetylamino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

xl) cyclo{Suc[1-(R)-2-(2-(S)-hydroxymethyl-pyrrolidin-1-yl)acetylamino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

xli) cyclo{Suc[1-(R)-2-(4-methyl-piperazin-1-yl)acetylamino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}

xlii) cyclo{Suc[1-(R)-2-(4-methyl-piperazin-1-yl)carbonylamino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]} or

xliii) cyclo{Suc[1-(R)-2-(1-oxo-thiomorpholin-4-yl)acetylamino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}.

30. (Previously Presented) Compounds according to Claim 23 wherein: R_4 represents a group COR_{13} wherein R_{13} is morpholine.

31. (Previously Presented) Compounds according to claim 30 represented by: xlvi) cyclo{Suc[1-(4-morpholino)carbonyl]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}.

32. (Previously Presented) Pharmaceutical compositions containing as active principle compounds of general formula (I) according to Claim 21 in combination with pharmaceutically acceptable carriers or excipients.

33. (Previously Presented) A method for the treatment of the bronchospastic component of asthma, cough, pulmonary irritation, intestinal spasms or local spasms of bladder, ureters during cystitis, kidney infections and colics wherein amounts of 0.1 to

10mg/kg body weight of an active principle represented by compounds of formula (I) according to Claim 21 are administered to the patient.

34. (Currently Amended) Monocyclic compounds of formula (I)

wherein:



(I)

X_1, X_2, X_3, X_4 are the same or different, and are selected from the group consisting of -CONR-, -NRCO-, $-CH_2$-NR-, and -NR-CH_2- where R is selected from the group consisting of H, C_{1-3} alkyl, and benzyl;

f and m are the same or different, and are a number selected from the group consisting of 0, 1 and 2;

R_1 and R_2, are the same or different, and represent:

$-(CH_2)_r$Ar where r is 0, 1 or 2 and Ar is an aromatic group selected from the group consisting of benzene, naphthalene, thiophene, benzothiophene, pyridine, quinoline, indole, furan, benzofuran, thiazole, benzothiazole, imidazole, benzoimidazole, optionally substituted with up to 2 substituents selected from the group consisting of C_{1-3} alkyl, C_{1-3} haloalkyl, C_{1-3} alkyloxy, C_{2-4} amino-alkyloxy, halogens, OH, NH_2, CN, and NR_6R_7, where R_6 and R_7, same or different, are H or C_{1-3} alkyl,

R_3 is-$(CH_2)_r$$Ar_1$ where r is 0, 1 or 2 and Ar_1 is an aromatic group selected from the group consisting of benzene, naphthalene, thiophene, benzothiophene, pyridine, quinoline, indole, furan, benzofuran, thiazole, benzothiazole, imidazole, and benzimidazole,

optionally substituted with up to 2 groups selected from the group consisting of C_{1-3} alkyl, C_{1-3} haloalkyl, C_{1-3} alkyloxy, C_{2-4} amino-alkyloxy, halogens, OH, NH_2, and NR_6R_7, where R_6 and R_7, same or different, are H or C_{1-3} alkyl,

R_5 is H,

R_4 is [$-NR_8R_9$;]-$N(R_{11})CO(CH_2)_h$ R_{12}[; or $-COR_{13}$;where R_8 is H or C_{1-3} alkyl; h is 0, 1, 2 or 3; and R_9 is selected from the group consisting of methanesulfonyl, tosyl, tetrahydropyranyl, tetrahydrothiopyranyl optionally mono or di-substituted by oxygen on the S atom, piperidyl, optionally substituted on the N-atom by a C_{1-3} alkyl, C_{1-3} acyl, aminosulfonyl, or methanesulfonyl; or a group $-(CH_2)_gR_{10}$ where g is 1, 2, or 3 and R_{10} is selected from the group consisting of morpholine, furan and CN;

or R_8 and R_9 together with the N atom to which they are linked form a piperazine optionally substituted at the other N atom by a C_{1-3} alkyl, C_{1-3} acyl or methanesulfonyl;]

where R_{11} is H [or C_{1-3} alkyl]; h is 0[,] or 1[, 2 or 3]; and R_{12} is selected from the group consisting of 1-tetrazolyl, 5-mercapto-tetrazol-1-yl, 1-triazolyl, furanyl, thiophenyl, morpholine, 4-hydroxy-piperidine, 4-carboxyamido-piperidine, 3-hydroxy-pyrrolidine, 2-hydroxymethylpyrrolidine, 4-methyl-piperazine, 4-aminosulfonyl-piperazine, 1-oxo-thiomorpholine and 4-hydroxy-cyclohexan-1-yl-amino; and

[R_{13} is a member selected from the group consisting of morpholine and piperazine optionally substituted by a C_{2-6} alkyl containing one or more hydroxy groups;]

their enantiomers and mixtures thereof, their diastereoisomers, and their pharmaceutically acceptable salts.

35. (Previously Presented) Compounds according to claim 34 represented by:

i) cyclo{Suc[1-(R)-2-(4-aminosulfonyl-piperazin-1-yl)acetylamino]-Trp-Phe-[(R)-NH-$CH(CH_2-C_6H_5)-CH_2NH$]} or

ii) cyclo{Suc[1-(R)-2-*(trans*--4-hydroxy-cyclohexan-1-yl-amino)acetylamino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2NH]}.